Bernas Stefanie N, Baldauf Henning, Wendler Sarah, Heidenreich Falk, Lange Vinzenz, Hofmann Jan A, Sauter Jürgen, Schmidt Alexander H, Schetelig Johannes
DKMS, Tübingen, Germany.
DKMS, Clinical Trials Unit, Dresden, Germany.
Int J Infect Dis. 2021 Apr;105:653-655. doi: 10.1016/j.ijid.2021.02.108. Epub 2021 Mar 2.
To determine the impact of the 32 bp deletion (CCR5Δ32) in the coding region of the C-C chemokine receptor 5 (CCR5) on the risk of contracting SARS-CoV-2 and severe COVID-19.
Cross-sectional study among stem cell donors registered with DKMS in Germany. Genetic information was linked to self-reported COVID-19 outcome data. Multivariable regression models were fitted to determine the risk of contracting SARS-CoV-2, severe respiratory tract infection (RTI) and respiratory hospitalization.
CCR5 information was available for 110 544 donors who were tested at least once for SARS-CoV-2; 5536 reported SARS-CoV-2 infection. For 4758 donors, the COVID-19 disease course was fully evaluable; 498 reported no symptoms, 1227 described symptoms of severe respiratory tract infection, of whom 164 required respiratory hospitalization. The distribution of CCR5Δ32 genotypes (homozygous wild-type vs CCR5Δ32 present) did not differ significantly between individuals with or without SARS-CoV-2 infection (odds ratio (OR) 0.96, 95% CI 0.89-1.03, P = 0.21) nor between individuals with or without symptomatic infection (OR 1.13, 95% CI 0.88-1.45, P = 0.32), severe RTI (OR 1.03, 95% CI 0.88-1.22, P = 0.68) or respiratory hospitalization (OR 1.16, 95% CI 0.79-1.69, P = 0.45).
Our data implicate that CCR5Δ32 mutations do not determine the risk of SARS-CoV-2 infections nor the disease course.
We registered the study with the German Center for Infection Research (https://dzif.clinicalsite.org/de/cat/2099/trial/4361).
确定C-C趋化因子受体5（CCR5）编码区32bp缺失（CCR5Δ32）对感染严重急性呼吸综合征冠状病毒2（SARS-CoV-2）和严重冠状病毒病2019（COVID-19）风险的影响。
对在德国DKMS登记的干细胞捐献者进行横断面研究。将遗传信息与自我报告的COVID-19结果数据相关联。采用多变量回归模型确定感染SARS-CoV-2、严重呼吸道感染（RTI）和因呼吸道疾病住院的风险。
110544名至少接受过一次SARS-CoV-2检测的捐献者有CCR5信息；5536人报告感染了SARS-CoV-2。对于4758名捐献者，COVID-19病程可完全评估；498人无症状，1227人描述有严重呼吸道感染症状，其中164人需要因呼吸道疾病住院。CCR5Δ32基因型（纯合野生型与存在CCR5Δ32）的分布在感染或未感染SARS-CoV-2的个体之间（优势比（OR）0.96，95%置信区间0.89-1.03，P = 0.21）、有或无症状感染的个体之间（OR 1.13，95%置信区间0.88-1.45，P = 0.32）、严重RTI的个体之间（OR 1.03，95%置信区间0.88-1.22，P = 0.68）或因呼吸道疾病住院的个体之间（OR 1.16，95%置信区间0.79-1.69，P = 0.45）均无显著差异。
我们的数据表明，CCR5Δ32突变不能决定感染SARS-CoV-2的风险和疾病进程。
我们在德国感染研究中心（https://dzif.clinicalsite.org/de/cat/2099/trial/4361）注册了该研究。
